Combined resection intraperitoneal chemotherapy
and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.
Some authors reported effective intraperitoneal chemotherapy
, but no clinical study is available about long term outcome.
Some chemotherapies are given directly into the abdominal cavity (called intraperitoneal chemotherapy
Recent years have seen a trend toward more aggressive management strategies that include multiple surgeries, complete peritonectomy, intraoperative intraperitoneal chemotherapy
, and additional cycles of postoperative chemotherapy.
Cytoreductive surgery and intraperitoneal chemotherapy
are treatment options for diffuse malignant mesothelioma, whereas most cases of localized malignant mesothelioma are cured by surgical excision.
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy
for diffuse malignancy peritoneal mesothelioma.
A sampling of topics; nanocapsules of platinum-based anticancer drugs, resistance to cisplain results from multiple mechanisms in cancer cells, differences in conformation and conformational dynamics between cisplatin and oxaliplatin DNA adducts, platinum compounds in lung cancer, oxaliplatin-based chemotherapy for colon cancer, platins in newly- diagnosed endometrial cancer, intraperitoneal chemotherapy
in ovarian cancer treatment, organic cation transporters 2 as mediators of cisplatin nephrotoxicity, and platinum drugs in children with cancer.
Combined with Cytoreductive Surgery: Nursing Management Targeted Toward Aspects of Symptom Distress
In a recent prospective study, cytoreductive surgery plus intraperitoneal chemotherapy
was better than intravenous chemotherapy alone, confirming two previous trials.
Key words: calretinin, cisplatin, HBME-1, intraperitoneal chemotherapy
, occupational cancer, peritonectomy.
Cheng A, Peng Z, Hong Z (1999) A pharmacokinetic study of teniposide in intraperitoneal chemotherapy
of ovarian cancer.
Interim data from a Phase I study of tgDCC-E1A in combination with intraperitoneal chemotherapy
support the good safety profile of the combined regimen and demonstrate a reduction in levels of CA-125, a marker for ovarian cancer, in six of seven patients who entered the study with CA-125 levels above 20 U/Ml.